Minimum costs to manufacture new treatments for COVID-19

INTRODUCTION: ‘Repurposing’ existing drugs to treat COVID-19 is vital to reducing mortality and controlling the pandemic. Several promising drugs have been identified and are in various stages of clinical trials globally. If efficacy of these drugs is demonstrated, rapid, mass availability at an aff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virus Erad
Autors principals: Hill, Andrew, Wang, Junzheng, Levi, Jacob, Heath, Katie, Fortunak, Joseph
Format: Artigo
Idioma:Inglês
Publicat: Mediscript Ltd 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7331548/
https://ncbi.nlm.nih.gov/pubmed/32405423
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars